United Therapeutics Corporation (UTHR)

Return on total capital

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 1,333,600 1,198,700 1,153,000 959,800 967,500 961,700 849,000 913,400 637,100 532,600 547,500 465,800 608,500 606,700 561,400 684,500 -135,600 -67,600 -96,600 -141,800
Long-term debt US$ in thousands 300,000 500,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 800,000 600,000 750,000 800,000 1,050,000
Total stockholders’ equity US$ in thousands 5,984,800 5,712,100 5,411,000 5,123,200 4,796,700 4,562,200 4,318,400 4,176,300 3,958,900 3,829,700 3,639,500 3,445,400 3,395,200 3,283,100 3,093,700 2,948,500 2,780,400 2,715,800 2,558,400 2,319,000
Return on total capital 21.22% 19.30% 18.56% 16.20% 17.29% 17.93% 16.59% 18.36% 13.39% 11.50% 12.33% 10.97% 14.50% 14.86% 14.42% 18.26% -4.01% -1.95% -2.88% -4.21%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $1,333,600K ÷ ($300,000K + $5,984,800K)
= 21.22%

United Therapeutics Corp's return on total capital has remained relatively stable over the past eight quarters, ranging from 16.48% to 18.26%. This indicates that the company has been effectively utilizing its total capital to generate returns for its investors. The highest return was recorded in Q1 2022 at 18.26%, while the lowest was in Q1 2023 at 16.48%. Overall, the company has consistently demonstrated strong performance in terms of generating returns relative to its total capital invested. However, further analysis and comparison with industry peers may provide additional insights into the company's overall financial health and efficiency.